- Home
- FUND vs EVMN Comparison
FUND vs EVMN Comparison
Compare FUND & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FUND | EVMN |
|---|---|---|
| Founded | 1988 | 2020 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.8M | 241.3M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | FUND | EVMN |
|---|---|---|
| Price | $9.75 | $5.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $22.33 |
| AVG Volume (30 Days) | 16.8K | ★ 808.3K |
| Earning Date | 01-01-0001 | 11-07-2026 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | N/A | ★ 75.23 |
| EPS | ★ 0.93 | N/A |
| Revenue | N/A | ★ $13,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.49 | ★ N/A |
| Revenue Growth | N/A | ★ 85.71 |
| 52 Week Low | $7.97 | $5.09 |
| 52 Week High | $10.99 | $33.20 |
Technical Indicators
Market Signals| Indicator | FUND | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 42.82 | 20.22 |
| Support Level | $9.39 | N/A |
| Resistance Level | $10.10 | $13.35 |
| Average True Range (ATR) | 0.22 | 0.39 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 30.68 | 3.53 |
Price Performance
Historical ComparisonAbout FUND Sprott Focus Trust Inc.
Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, the Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.